Sign In
Buy HOOK
$1.15
+0 (+0%)
At Close: Jun 03, 2026
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023
07:00am, Wednesday, 08'th Mar 2023
NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus plat
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
07:00am, Tuesday, 07'th Feb 2023
NEW YORK and VIENNA, Austria, Feb. 07, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavi
HOOKIPA Pharma Inc. (HOOK) Reports Q3 Loss, Misses Revenue Estimates
09:47am, Monday, 14'th Nov 2022
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of -4.17% and 31.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock
HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022
07:00am, Monday, 07'th Nov 2022
NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus
How to Find Popular Penny Stocks Right Now
06:00am, Friday, 21'st Oct 2022
Use these tips for finding popular penny stocks to buy right now The post How to Find Popular Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.
Why Is Hookipa (HOOK) Stock Up 26% Today?
10:29am, Thursday, 20'th Oct 2022
Hookipa (NASDAQ: HOOK ) stock is rocketing higher on Thursday after reaching a strategic collaboration and license agreement with Roche (OTCMKTS: RHHBF ). That agreement has the two companies working
HOOKIPA Pharma Inc. (HOOK) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Thursday, 29'th Sep 2022
HOOKIPA Pharma Inc. (HOOK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
07:00am, Wednesday, 07'th Sep 2022
NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapies based on its proprietary arenavirus platfor
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates
12:15pm, Thursday, 11'th Aug 2022 Zacks Investment Research
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 36.11% and 21.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Misses Revenue Estimates
09:47am, Thursday, 11'th Aug 2022
HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 36.11% and 21.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex (CDXC) Reports Q2 Loss, Lags Revenue Estimates
09:45pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
12:35pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA to Participate in the JMP Securities Life Sciences Conference
11:00am, Thursday, 09'th Jun 2022 GlobeNewswire Inc.
NEW YORK and VIENNA, Austria, June 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary are
